Recent advances in drug delivery systems for enhancing drug penetration into tumors
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The emergence of nanomaterials for drug delivery provides the opportunity to avoid the side effects of systemic drug administration and injury caused by the removal of tumors, delivering great promise for future cancer treatments. However, the efficacy of current nano drugs is not significantly better than that of the original drug treatments. The important reason is that nano drugs enter the tumor vasculature, remaining close to the blood vessels and unable to enter the tumor tissue or tumor cells to complete the drug delivery process. The low efficiency of drug penetration into tumors has become a bottleneck restricting the development of nano-drugs. Herein, we present a systematic overview of recent advances on the design of nano-drug carriers in drug delivery systems for enhancing drug penetration into tumors. The review is organized into four sections: The drug penetration process in tumor tissue includes paracellular and transcellular transport, which is summarized first. Strategies that promote tumor penetration are then introduced, including methods of remodeling the tumor microenvironment, charge inversion, dimensional change, and surface modification of ligands which promote tissue penetration. Conclusion and the prospects for the future development of drug penetration are finally briefly illustrated. The review is intended to provide thoughts for effective treatment of cancer by summarizing strategies for promoting the endocytosis of nano drugs into tumor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“The low permeability of solid tumors has become a bottleneck restricting the development of nanodrugs (Maeda et al., 2000).”
BackgroundType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 1×
“In addition, the microenvironment also contains fibroblasts (Kalluri & Zeisberg, 2006), immune cells (Galon et al., 2006), vascular endothelial cells (Palmer et al., 1988), stellate cells, and other cells, which affect the efficacy of nano-drugs.”
BackgroundPoly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533 · cited 4×
“By comparing the penetration of PEGylated nanoparticles with different charges in tumor tissues, Miura et al. (2014) found that weak positive charges on the surface of nanoparticles greatly increased their capability to penetrate tumor tissues.”
MethodInfluentialCisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335 · cited 1×
“Chemotherapy using small molecule drugs, such as doxorubicin (Cohen et al., 2012), camptothecin (Liu et al., 2008), paclitaxel (Von Hoff et al., 2011), or cisplatin (Siddik, 2003) are the most commonly-used anti-tumor treatments (Sherman-Baust et al., 2011).”
BackgroundThe effect of particle design on cellular internalization pathways
Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918 · cited 5×
“MMP-9 response charge reversal gel system showing a more rapid rate of endocytosis rate and representing a passive PEGylated gel system (Gordon et al., 2018).”
BackgroundMethodInfluentialProgenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600 · cited 1×
“Because diffusion rate is inversely proportional to diameter, the diffusion of large nano-drugs is considerably smaller than that of small molecules (Ceradini et al., 2004).”
BackgroundAccumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Cited by
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060571 · Cited by 623
“Thus, complementary active targeting with passive targeting, enhancing circulation, tumor accumulation, drug penetration in the target cell and finally release into the cytoplasm for action through circulation, accumulation, penetration, internalization, and release (CAPIR) cascade to improve the EPR effect is necessa…”
BackgroundTewabe, A., Abate, A., Tamrie, M., Seyfu, A., & Abdela Siraj, E. (2021) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s313968 · Cited by 375
Scale-up polymeric-based nanoparticles drug delivery systems: Development and challenges
Herdiana, Y., Wathoni, N., Shamsuddin, S., & Muchtaridi, M. (2022) · OpenNano · doi:10.1016/j.onano.2022.100048 · Cited by 329
Nanoparticles in Clinical Translation for Cancer Therapy
Mundekkad, D., & Cho, W. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031685 · Cited by 305
The design of small-molecule prodrugs and activatable phototherapeutics for cancer therapy
Han, H.-H., Wang, H.-M., Jangili, P., Li, M., Wu, L., Zang, Y., Sedgwick, A. C., Li, J., He, X.-P., James, T. D., et al. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00673a · Cited by 299
Metadata
- Authors
- He, B., Sui, X., Yu, B., Wang, S., Shen, Y., & Cong, H.
- Venue
- Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2020-01
- Volume
- 27
- Issue
- 1
- Pages
- 1474-1490
- ISSN
- 1071-7544 (ISSN-L)
- 1521-0464
- OpenAlex
- W3093565903
- Cited by
- 134
- References
- 21
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent advances in drug delivery systems for enhancing drug penetration into tumors. https://app.cochat.ai/papers/10.1080/10717544.2020.1831106
- The paper
- He, B., Sui, X., Yu, B., Wang, S., Shen, Y., & Cong, H. (2020). Recent advances in drug delivery systems for enhancing drug penetration into tumors. Drug Delivery. https://doi.org/10.1080/10717544.2020.1831106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.